

Patient Organization Funding ^[1]

Novartis is committed to open dialogue and transparent exchange of information with patient organizations as detailed in our [Commitment to Patients and Caregivers](#) ^[2]. We see patient organizations as a key partner in our decision-making throughout the medicines lifecycle. We believe that incorporating the patient perspective in our decision-making can help to develop better medicines for the benefit of patients.

Novartis engages with patient organizations in recognition of their unique skills, expertise and perspectives. We commit to fully respect their independence and integrity. Patient organizations are neither required nor encouraged to promote or endorse Novartis products and services. We do not initiate or drive the initiation of new patient organizations and strive not to be the sole funder of any patient organization. When engaging patient organization representatives, Novartis will compensate their time and expenses according to local laws and regulations on a fair market value basis.

Novartis annually discloses monetary and non-monetary support to patient organizations around the globe by June 30 in compliance with the [Code of Practice](#) ^[3] on Relationships between the Pharmaceutical Industry and Patient Organizations set by the European Federation of Pharmaceutical Industries and Associations ([EFPIA](#) ^[4]). Novartis endorses the EFPIA Code and other relevant industry codes ^[5] to help enable its relationships with patient organizations to take place in an ethical and transparent manner.

- [Download the 2020 report \(PDF 1.5 MB\)](#) ^[6]
- [Download the 2019 report \(PDF 2.1 MB\)](#) ^[7]
- [Download the 2018 report \(PDF 3.0 MB\)](#) ^[8]

[Read our position on patient organizations interaction and support \(PDF 0.2 MB\)](#) ^[9]

[Global Methodological Note 2020 \(PDF 0.3 MB\)](#) ^[10]

[Read the EFPIA Code](#) ^[4]

Novartis is committed to supporting patient groups responsibly.

Source URL: <https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure/patient-group-funding>

Links

[1] <https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure/patient-group-funding>

[2] <https://www.novartis.com/our-focus/patients-caregivers/novartis-commitment-patients-and-caregivers>

[3] <https://efpia.eu/relationships-code/patient-organisations/>

[4] <https://www.efpia.eu/>

[5] <https://www.phrma.org/codes-and-guidelines/phrma-principles-on-interactions-with-patient-organizations>

- [6] <https://www.novartis.com/sites/www.novartis.com/files/patient-support-web-report-2020.pdf>
- [7] <https://www.novartis.com/sites/www.novartis.com/files/patient-support-web-report-2019.pdf>
- [8] <https://www.novartis.com/sites/www.novartis.com/files/patient-support-web-report-2018.pdf>
- [9] <https://www.novartis.com/sites/www.novartis.com/files/novartis-position-on-collaborating-with-patient-organizations.pdf>
- [10] <https://www.novartis.com/sites/www.novartis.com/files/novartis-patient-organization-methodological-note.pdf>